Objectives: The indication for screening for valvular heart disease in patients taking cabergoline is based on evidence from patients with Parkinson's disease on high-dose medication. However, current patients take much lower doses for indications such as hyperprolactinaemia disorders. Contemporary guidelines for echocardiogram monitoring in patients taking cabergoline are conflicting. This study aimed to review current clinical practice in our area regarding echocardiographic screening and to review the literature examining the evidence of valvular heart disease in patients taking lower dose cabergoline. Methods: This was a retrospective study of all patients with hyperprolactinaemia disorders prescribed cabergoline in a single UK NHS health board between January 2014 and July 2015. The proportion of patients receiving baseline and follow-up echocardiograms was recorded. A review of the published literature was carried out using the databases EMBASE and Medline to examine the current evidence for the effect cabergoline has on cardiac valves in patients treated for hyperprolactinaemia disorders. Results: The mean age was 51.7 ± 16.5 years with a 64.4% female predominance. The mean duration of therapy was 5.9 years ± 4.1 years. Of the total cohort (n = 45), two (4.4%) patients had an initial baseline echocardiogram and five (13.2%) had follow-up echocardiograms every 24 months. Of the 25 articles identified, 12 showed no clinically significant evidence of valvular dysfunction in the cabergoline group groups. Of the remaining 13 articles, evidence for valvular changes was confined to high cumulative dose cabergoline patients and there was only one confirmed case of 'cabergoline associated valvulopathy' described. Conclusions: Clinically significant valvular dysfunction is uncommon and generally only reported in high cumulative dose treatment groups. We propose that clearer national guidelines are required and that echocardiogram screening be reserved for patients who are high risk, are taking a high weekly dose (⩾2 mg cabergoline weekly) or high cumulative dose.
Introduction
Cabergoline is an ergot derived orally active synthetic dopamine receptor agonist (D2) used in the treatment of prolactinomas, other hyperprolactinaemic states and previously in higher doses in patients with Parkinson's disease. 1 Early studies of cabergoline reported an association with cardiac valve incompetence and raised sufficient concerns to lead to a recommendation for valve screening. 2, 3 Agonist activity at the (5-HT)2B serotonin receptor leading to fibroblast proliferation and fibrosis has been proposed as a pathological mechanism of this adverse effect. 4 In general, these studies showed a dose-related effect leading to moderate to severe regurgitation, principally of the left heart. 2, 5 The dose of cabergoline in these studies was typically greater than 3 mg per day with a cumulative dose of 3 g. 6 However, subsequent studies have failed to show convincing evidence of valve dysfunction in patients treated with lower doses of cabergoline, such as used in the treatment of prolactinomas and other hyperprolactinaemia disorders. 7 The dose now used in these conditions is significantly lower due to its high potency for suppressing prolactin and prolonged elimination half life, allowing for once weekly or even less frequent administration. 8, 9 Doses typically range from 0.5 to 4 mg weekly compared with doses of up to 3 mg daily historically used in Parkinson's disease. 10 Guidelines on the need for echocardiographic surveillance for acquired cardiac valve dysfunction in patients treated with cabergoline vary.
The manufacturer's summary of product characteristics (SPC) for cabergoline states that valvulopathy has been associated with cumulative doses and prolonged use. It recommends that 'All patients must undergo a cardiovascular evaluation, including echocardiogram to assess the potential presence of asymptomatic valvular disease' and that 'following treatment initiation, the first echocardiogram must occur within 3-6 months, thereafter, the frequency of echocardiographic monitoring … must occur at least every 6-12 months'. 3 The US Food and Drugs Administration (FDA) also follow this recommendation. 11 However, in the UK there are no National Institute for Clinical Excellence guidelines on echocardiogram monitoring for patients taking cabergoline. The Medicines and Healthcare Products Regulatory Agency (MHRA) published a public assessment report on cabergoline, following the same recommendations as the FDA and the SPC. 12 None of the above guidance considers dose, however the 2011 endocrine society guidelines state that echocardiogram surveillance is probably not needed in those taking less than 2 mg per week. 13 The UpToDate topic on the management of hyperprolactinaemia takes a similar standpoint, suggesting 'using the lowest dose of cabergoline necessary to lower prolactin to normal' and that 'cardiac ultrasonography should be ordered approximately every 2 years in patients who take larger than typical doses of cabergoline (e.g. >2 mg per week)'. 14 There is inconsistent advice resulting in uncertainty within clinical practice surrounding which patients should receive echocardiogram screening, especially given that high-dose cabergoline is rarely used in clinical practice due to availability of alternative therapies for Parkinson's disease.
Aims
This study aimed to review current clinical practice in our area to determine if patients with hyperprolactinaemia disorders were receiving echocardiographic screening in line with national and international recommendations and to review the literature examining the current evidence for the effect cabergoline has on cardiac valves in patients treated for hyperprolactinaemia disorders. Furthermore, we sought to discover if other centres have systems in place to undertake echocardiographic screening in patients taking cabergoline.
Methods

Design and setting of service evaluation
This was a retrospective study of all patients with hyperprolactinaemia disorders prescribed cabergoline in NHS Highland (North) between January 2014 and July 2015 inclusive. This health board provides all public health care for a population in excess of 250,000 people in a remote and rural setting. All 14 health boards in NHS Scotland were contacted to establish if they had local guidelines or protocols on echo surveillance for patients taking cabergoline.
Case selection
Patients were identified who had been prescribed cabergoline from the prescribing information system (PIS). PIS holds the full dataset for community pharmacy prescribing and dispensing in Scotland. It is populated from payment processing data produced by the Practitioner Services Division, comprising scanned prescription forms and electronic message data. A clinical case notes review was undertaken to determine the underlying clinical condition and dose of cabergoline.
Clinical notes and review of EchoPac (GE healthcare Vs 113) were used to determine echocardiogram indication, scan frequency and results.
Data handling and statistics
Data were entered into an Excel spreadsheet (Microsoft Excel 97-2003) . Descriptive statistics were used to show what proportion of baseline and follow-up echocardiograms were performed. Data are expressed as mean ± standard deviation unless otherwise stated. For continuous measures a T-test difference in means between groups was performed. The cohort was subdivided into those on 'high-dose' (⩾2 mg weekly) and 'low-dose' (<2 mg a week) cabergoline, those patients that received echocardiogram surveillance and those that did not. This distinction was based on the available evidence on risk for valvular heart disease in this population and the clinical practice guidelines published by the Endocrine Society. 13 The duration of follow up for patients currently taking cabergoline was from the date of their first prescription until the last date of medical contact. For those patients not currently taking cabergoline the duration of follow up was from the date of their first prescription until their last prescription.
Patients were considered to have had an appropriate baseline echocardiogram if an echocardiogram was performed up to 6 months prior to the commencement of cabergoline therapy. The interval between echocardiograms was taken from the dates the procedures were performed or from the date of the first cabergoline prescription until the date of the first echocardiogram. In the absence of clear and consistent guidelines we took a pragmatic (and lenient) approach to set the standard for frequency of follow-up echocardiogram at every 2 years. If patients had stopped taking cabergoline within 2 years of starting they were not included in the follow-up echocardiogram analysis.
Ethics
This was a service evaluation and therefore ethical approval was not required.
Literature review
A review of the published literature was carried out using the databases EMBASE and Medline (1946 Medline ( -2016 . The search was undertaken using the terms 'cabergoline and heart valve', 'cabergoline and cardiac', 'ergolines and cardiac' and 'ergolines and heart valve'. All of the relevant data returned were published between 2008 and 2016. A grey literature search was performed and reference lists of identified articles were scrutinized.
Studies from peer reviewed journals published in English (or with English translation) examining the association between cardiac valve abnormalities and cabergoline in patients with hyperprolactinaemia disorders were included. The relevant data were collected from the published full text. Case reports were excluded. Databases were last searched 1 July 2016. This is shown in Figure 2 .
When available, the variables included in the summary of relevant articles included:
• date of publication, • type of study,
• study participant numbers, • age, • duration of treatment, • cumulative dose of cabergoline, • weekly dose of cabergoline.
When available, the outcomes included in the summary of relevant articles included:
• difference in prevalence of valvular dysfunction, • difference in means, • odds ratio (OR), • relative risk (RR).
Studies were not individually assessed for bias. The study summaries were presented in tabulated form. This was not registered as a systematic review.
Results
A total of 56 patients were identified as having been prescribed cabergoline between January 2014 and July 2015. Of these, 11 patients were excluded leaving 45 patients eligible for analysis ( Figure 1 ). Clinicians in our institution report variation in their approach to echocardiogram surveillance. Some are influenced by MHRA guidance and the Society For Endocrinology 2011 position, aiming to perform echocardiograms at baseline and 1-2 yearly. Others are influenced by the available literature and perform baseline echocardiograms and only perform surveillance follow-up echocardiograms in at-risk patients or those on higher-dose cabergoline.
Patient demographics, indication and dose
The mean age was 51.7 ± 16.5 years, with a 64.4% female predominance. The reasons for cabergoline use are shown in Table 1 along with the recommended British National Formulary (BNF) doses. The mean duration of therapy was 5.9 years ± 4.1 years.
Of the total cohort (n = 45) only two (4.4%) patients with hyperprolactinaemia disorders had an appropriate initial baseline echocardiogram performed before commencing cabergoline. Furthermore, only five (13.2%) patients had appropriate follow-up echocardiograms every 24 months (average interval 0.8 ± 0.5 years). A total of seven patients were excluded from all followup analysis as the duration of treatment was less than 24 months and they would not have required follow up. A total of 80 echocardiograms were performed for all patients during the follow-up time period. The vast majority of echocardiograms performed showed no valvular abnormalities. Mild to moderate mitral, tricuspid and aortic regurgitation were reported in a small number of studies, as was slight mitral leaflet calcification, mildly thickened aortic valve, mild aortic stenosis and aortic regurgitation, which were of no clinical significance.
Patients who received echocardiogram assessment compared with those who did not Of the patients who had appropriate baseline echocardiograms (n = 2) these were all undertaken specifically for cabergoline monitoring; that is, no patients had concomitant valve disease. The mean age was 45.5 years ± 14.8 years. The mean age of those who did not have any baseline echos (n = 43) was 52.0 years ± 16.7 years. There was no statistically significant difference between the age of the two groups (p = 0.59).
Of the patients who had at least one follow-up echocardiogram (n = 25) the majority were for cabergoline monitoring with other indications, including general valve assessment, assessment of heart murmurs, presurgery assessment, left ventricular assessment and post non ST elevation myocardial infarction valve replacement. The mean age was 55.8 ± 16.5 years. The patients who had no follow-up echocardiograms (n = 13) had a mean age of 49.5 ± 17.2 years. There was no statistically significant difference between the age of the two groups (p = 0.26).
Patients on high-and low-dose cabergoline
High-dose (⩾2 mg/week) cabergoline was prescribed in five (11.1%) patients. The mean duration of treatment was 7.1 ± 3.4 years. The mean age was 63.0 ± 11.6 years. Of these five patients, 0 (0.0%) had an initial echocardiogram before starting treatment. Regarding appropriate follow up, one (20%) patient had no follow-up echocardiogram and one (20%) patient had follow up at least every 24 months with three echocardiograms performed with an average interval of 0.7 ± 0.4 years. Of the remaining three patients (60%), 12 echocardiograms were performed with an average interval of 2.0 ± 1.0 years. A total of 15 echocardiograms were performed during the follow-up period. If guidelines had been followed, this should have been 21. There was no statistically significant difference between the age of the two groups (p = 0.11). Table 2 shows a summary of the total number of recommended and observed echocardiograms.
Literature review
From the database search, 439 articles were identified with 334 remaining after duplicates were removed. Of these, 286 were excluded on title and abstract. This left 48 articles included in the full article review. Of these, 23 were excluded leaving 25 relevant articles for analysis. Table 3 shows a summary of relevant published studies to date. There were no randomized control studies identified. Of the 25 articles reviewed, 12 showed no valve changes or dysfunction as a result of cabergoline use. Of the remaining 13 articles describing valve changes in patients taking cabergoline, only one confirmed case in one paper was defined as 'cabergoline-associated valvulopathy'.
Discussion
This service evaluation highlighted significant variation in practice with regard to echocardiographic surveillance of patients with hyperprolactinaemia disorder treated with cabergoline in our area. Very few patients had an initial baseline echocardiogram or appropriate follow-up echocardiograms based on current guidelines. This is perhaps not surprising given the variation in guideline advice and the paucity of clinical data. Furthermore, within our clinical service there is no formal system to monitor echocardiogram surveillance in these patients. Currently, echocardiograms are booked by the responsible clinician as part of the patient's outpatient clinic review on an ad hoc basis. However, our service appears to be similar to other areas, with none of the 14 health boards in NHS Scotland having protocols to guide decision making regarding echo surveillance. Having surveyed the responsible clinicians it is clear that the growing body of literature on this subject is influencing practice. It may be the case that the very low rate of baseline echocardiograms reflects the fact that clinicians are risk stratifying patients and, as patients are generally started at a lower dose titrated up over several months, it is difficult to identify high risk patients prior to treatment initiation.
Whilst most echocardiograms showed no valvular abnormalities some were reported in a small number of studies, which in the most part were non-progressive and not of any clinical significance. This study was not designed to comment on whether these changes were above the baseline incidence for this population.
The literature review revealed inconsistent results. Of the 25 articles identified, 12 showed no clinically significant change in valvular function following treatment with cabergoline. These were a mixture of case-controlled, cross-sectional, prospective multicentre control matched and single arm prospective studies. They predominantly looked at valve regurgitation, valve thickening and mitral valve tenting area (area between the mitral annulus and the leaflets body and is a marker of regurgitation, subvalvular remodelling and leaflet thickening).
The remaining 13 articles were a mixture of case-controlled, cross-sectional and case-record Table 3 .
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Results
Cabergolineassociated valvulopathy demonstrated?
Yarman et al. 28 Retrospective Cabergoline group (n retrospective studies. They also predominantly looked at valve regurgitation, valve thickening and mitral valve tenting area.
Only one study 24 demonstrated a case of severe mitral regurgitation that had the associated valve thickening due to cabergoline. It is important when discussing the above papers that to meet the definition of cabergoline-associated valvulopathy you must determine there is 'the triad of moderate or severe regurgitation, with a restricted and thickened valve'. 7 One study, 1 showed no significantly increased risk of clinically relevant valvular regurgitation or leaflet thickening but did report a higher mitral valve tenting area in patients receiving cabergoline. Another study 25 showed an increase in mitral valve tenting area and an increase in mild tricuspid regurgitation (7.8% versus 0.0%) in the cabergoline group compared with controls.
Four studies reported an increase in mild to moderate tricuspid valve regurgitation and mild pulmonary valve regurgitation at high cumulative doses. Of these, one study 15 showed a statistically significant increase in mild tricuspid and mild pulmonary regurgitation in the cabergoline group at a mean cumulative dose of 311 mg. One study 17 reported a statistically significant increase in moderate tricuspid regurgitation in the cabergoline group at cumulative doses greater than 280 mg. One study 30 reported an increase in mild tricuspid regurgitation in the cabergoline group taking cumulative doses of cabergoline greater than 180 mg (p = 0.024). One study 31 reported a single case of moderate mitral regurgitation in the cabergoline group at a cumulative dose of 130 mg.
Two studies, a cross-sectional study 19 and its 2-year single-arm follow up, 26 pooled all patients taking a dopamine agonist and reported a statistically significant increase in aortic valve calcifications and mild tricuspid regurgitation.
One study 21 showed no significant differences in valvular function in the cabergoline group compared with controls but found that female patients had a higher prevalence of mild tricuspid regurgitation than female controls and male patients had a higher prevalence of trace tricuspid regurgitation than male controls. These valvular regurgitations were not clinically significant and showed no correlation to dose or duration. One study 29 showed no statistically significant difference in clinically relevant valve regurgitation. However, subclinical valve fibrosis occurred more often in the cabergoline-treated group compared with controls.
One study 9 showed 2.6% had a moderate regurgitation or stenosis of any valve. However, the investigators concluded the triad of cabergolineassociated valvulopathy was not present.
One study 7 showed five cases of valvular thickening but none of them met the definition of cabergoline-associated valve disease.
Therefore, it can be seen that the risk of clinically significant valvular dysfunction reported in the literature is very low. This brings into question the need for echocardiogram surveillance in these patients. Whilst further studies are required to quantify with certainty whether there is a clinically significant risk of valvular heart disease, the current evidence does not support this and suggests that the existing guidance for echocardiogram surveillance may be leading to many unnecessary echocardiograms in this group of patients. This is similar to the findings of previously reported literature reviews.
Based on these findings, we challenge the current echocardiogram recommendations and suggest that patients could be stratified into high-dose (⩾2 mg weekly) and low-dose (<2 mg weekly) cohorts to determine the need for echocardiogram surveillance.
If appropriate 2 yearly follow-up echocardiogram surveillance was only performed on patients taking high-dose cabergoline (⩾2 mg weekly), we estimate that 40 echocardiograms could be saved over a 2-year period in our patient cohort. This would equate to £4000 worth of activity in our health board (population 250,000). While this may seem modest, if our results were extrapolated to Scotland (population 5.5 million), this would be equivalent to approximately £100,000 of activity per annum. In addition to this, unnecessary screening could result in additional expense and inconvenience to patients and may increase anxiety. A reduction in unnecessary echocardiograms in an already pressured physiology service would seem desirable and is a key objective in the Scottish Government's current Healthcare Science National Delivery Plan.
Limitations
This was a single-centre study and therefore there is a risk that our results are not generalizable. However, our hospital provides care for all patients of our area and apart from one patient whose area was provided solely in a tertiary centre, it is unlikely that we have missed any patients. Cases were identified from the PIS which covers all community pharmacy prescribing and dispensing in Scotland. This system will not cover private prescriptions but it is unlikely that these occur in this patient group and thus we are confident that we have captured all relevant patients. Some patients were started on cabergoline before (2007) the publication of the pivotal studies linking cabergoline to valvular dysfunction. It may have been the case that clinicians at this time were unaware of the need for echocardiogram surveillance. It is not clear whether this was included on the SPC at the time.
Author recommendations
We propose that clearer national guidelines are promoted and that individual echocardiography departments are empowered to challenge the use of inappropriate surveillance. We also suggest that a national survey be carried out to look at the variations in clinical practice for echocardiogram surveillance for these patients.
In our institution, we plan to review the current guidelines and discuss this at a local level with the aim to set recommendations for echocardiogram screening only in at-risk patients. We recommend that echocardiogram surveillance should be reserved for those with known valvular heart disease or an audible murmur and those on doses of at least 2 mg weekly of cabergoline or a high cumulative dose.
We recommend that high dose patients should receive follow up echocardiograms at 2 yearly intervals, in line with previous guidance. As patients are generally started at a lower dose, which is titrated up over several months, it may be a challenge to identify high dose patients and to allocate baseline echos prior to treatment initiation. Patients with abnormal cardiovascular examination or known cardiac valve pathology should receive a baseline echocardiogram within 6 months prior to starting cabergoline and then follow up echocardiograms at 2 yearly intervals.
Conclusion
In our evaluation of a clinical service covering around 250,000 patients we found significant variation in practice, with very few patients receiving appropriate initial or follow-up echocardiograms. However, a review of the literature suggests that there is little evidence to support the link between low-dose cabergoline treatment for hyperprolactinaemia disorders and clinically significant valvular heart disease and we are aware of only one case where clinically important valvular heart disease developed. We suggest that the value of echocardiographic screening in patients receiving low-dose cabergoline (<2 mg/week) is limited and should be discontinued. It is also apparent that organizations and departments managing patients on high-dose cabergoline should establish robust recall systems to ensure appropriate monitoring during treatment.
